Diffusion-weighted MR imaging in comparison to integrated [18F]-FDG PET/CT for N-staging in patients with lung cancer

Pauls, Sandra; Schmidt, Stefan A.; Juchems, Markus; Klass, Oliver; Luster, Markus; Reske, Sven N.; Brambs, Hans-Juergen; Feuerlein, Sebastian

doi:10.1016/j.ejrad.2010.09.001

Cited by 57 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET/CT has a greater tendency to overstage (higher number of false-positives) than MR imaging, which gives a higher number of false-negatives. MR imaging, with or without diffusion MR imaging, shows moderate correlation with PET/CT [ 33 ] . The detectable size of a metastatic thoracic lymph node with the current available technology is approximately 4–5 mm for both diffusion MR imaging and PET/CT.…”

Section: Clinical Applicationsmentioning

confidence: 99%

Diffusion magnetic resonance imaging of chest tumors

Razek¹

2012

Cancer Imaging

View full text Add to dashboard Cite

This review provides an overview of the current status of the published data on diffusion magnetic resonance (MR) imaging of chest tumors. Diffusion MR imaging is a non-invasive imaging technique that measures the differences in water mobility in different tissue microstructures and quantifies them based on the apparent diffusion coefficient. Diffusion MR imaging has been used for the characterization, grading and staging of lung cancer as well as for differentiating central tumors from post-obstructive consolidation. In addition, this technique helps in differentiating malignant from benign pulmonary and mediastinal tumors as well as in the characterization of pleural mesothelioma and effusion. Diffusion MR imaging can be incorporated into routine morphological MR imaging to improve radiologist confidence in image interpretation and to provide functional assessments of chest tumors during the same examination. Diffusion MR imaging could be used in the future as a functional imaging technique for tumors of the chest.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Diffusion magnetic resonance imaging of chest tumors

Razek¹

2012

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…Tumors have less diffusion of water due to increased cellularity, more macromolecular proteins and less extracellular space and hence lower apparent diffusion coefficient [22]. Nomori et al reported lower rate of false positives (FPs) and a higher accuracy of diffusion-weighted imaging MRI as compared with PET-CT in mediastinal staging of NSCLC [23], but these results have not been replicated by others [24]. Further work is needed to determine whether this technology will be useful in routine mediastinal staging of NSCLC.…”

Section: Mrimentioning

confidence: 99%

Mediastinal staging of non-small-cell lung cancer

Dhillon

Yendamuri

2011

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

“…Yet another study showed that the quantitative and qualitative sensitivity, specificity, and accuracy of STIR turbo SE imaging were not significantly different from those of FDG-PET/CT. However, the combina- Since 2008, DWI was introduced as another promising MR technique for this purpose (Hasegawa et al 2008;Nomori et al 2008;Ohno et al 2011b;Pauls et al 2012). Sensitivity, specificity, and accuracy of DWI reportedly range, on a per-patient basis, from 77.4% to 80.0%, 84.4% to 97.0%, and 89.0% to 95.0%, respectively, and these results appear to be equal to or better than those for FDG-PET or PET/CT (Hasegawa et al 2008;Nomori et al 2008;Ohno et al 2011b;Pauls et al 2012).…”

Section: Mr Assessment Of N Classificationmentioning

confidence: 99%

Lung Cancer

Ohno¹,

Koyama²,

Dinkel³

2016

MRI of the Lung

View full text Add to dashboard Cite

Since the publication of the Radiologic Diagnostic Oncology Group Report (RDOG) in 1991, the clinical application of pulmonary magnetic resonance (MR) imaging to patients with lung cancer has been limited. MDCT has been much more widely available for staging of lung cancer in clinical situations. Traditionally, FDG-PET or PET/CT is the only modality that reveals biological glucose metabolism of lung cancer, and ventilation and/or perfusion scintigraphy is the only modality that demonstrates pulmonary function. However, recent advances of MR systems and utilization of contrast media make it possible to overcome the limitation of chest MR imaging. Therefore, in the last years, several investigators have demonstrated the significant comprehensive potential of MR imaging to substitute for MDCT and nuclear medicine examinations in lung cancer staging. Currently, MR imaging in lung cancer patients can be applied for (1) detection of pulmonary nodules, (2) characterization of solitary pulmonary nodules, and (3) assessment of TNM classification in routine clinical practice. We believe that further basic studies, as well as clinical applications of newer MR techniques, will play an important role in the future management of patients with lung cancer including MRI.

show abstract

Diffusion-weighted MR imaging in comparison to integrated [18F]-FDG PET/CT for N-staging in patients with lung cancer

Cited by 57 publications

References 24 publications

Diffusion magnetic resonance imaging of chest tumors

Diffusion magnetic resonance imaging of chest tumors

Mediastinal staging of non-small-cell lung cancer

Lung Cancer

Contact Info

Product

Resources

About